Supercharging a New FDA: Marty Makary on Science, Power & Patients

Episode Summary

Executive Summary: FDA Commissioner Marty Makary outlined an aggressive reform agenda centered on speeding drug approvals, using AI and continuous trials, cutting biosimilar and OTC barriers, and rebuilding public trust after COVID-era skepticism. He also defended major shifts in food policy, vaccines, NIH funding priorities, and post-market safety monitoring, framing the FDA as a faster, more transparent referee focused on cures, access, and competitiveness versus China.

Main Topics: FDA modernization and speed of approval (Priority: 5/5): Makary argued the FDA must abandon slow, legacy workflows and use AI, Bayesian methods, continuous trials, and streamlined reviews to shorten drug development timelines and reduce unnecessary delays. China and global biotech competitiveness (Priority: 5/5): He framed biotech as a geopolitical race and said the U.S. was falling behind China and others due to red tape, slow IRBs, and fragmented contracting, pushing centralized review and faster phase 1 pathways. Food policy and real-food guidance (Priority: 4/5): He described the food pyramid as distorted by dogma and industry influence, saying the administration is re-centering protein, real food, and fewer ultra-processed ingredients to address childhood chronic disease. Vaccines, trust, and the revised schedule (Priority: 4/5): Makary defended reducing the schedule to a list of core essential vaccines, arguing the U.S. recommendation set is unusually large and that trust was damaged by COVID-era absolutism and paternalism. Drug pricing, OTC access, and biosimilars (Priority: 5/5): He linked lower prices to most-favored-nation pricing, more over-the-counter access, and faster biosimilar approvals, arguing competition and transparency will pressure prices down. NIH funding priorities and research reallocation (Priority: 3/5): He claimed NIH funding should shift away from DEI-description work and toward root causes like microbiome, food, sleep, environmental exposures, and disease prevention. Cell and gene therapy, autism, and emerging science (Priority: 4/5): The discussion covered flexible manufacturing for bespoke therapies, CAR-T and gene editing, autism hypotheses involving folate and microbiome, and the FDA’s willingness to issue priority vouchers for promising breakthroughs.

Key Arguments: The FDA can materially speed cures by reducing redundant requirements, digitizing workflows, and using AI/Bayesian tools to make earlier decisions. The U.S. is losing biotech ground to China and Australia because of slow IRBs, fragmented contracting, and excessive regulatory burden. One pivotal trial can often provide enough statistical power, saving time and $100M-$300M per program versus a default two-trial model. Animal testing requirements are often inefficient and misleading; computational models and organ-on-a-chip systems can be better predictors. Continuous post-market surveillance should allow faster detection of safety signals and support faster approval thresholds. The revised vaccine schedule aims to restore trust by emphasizing “core essential” vaccines rather than an expansive all-doses approach. Food policy should prioritize protein, whole foods, and lower-processed diets; the old pyramid overemphasized saturated fat and ignored refined carbohydrates. Drug pricing can fall through MFN pricing, biosimilar acceleration, and more OTC switches that expose prices to consumer competition. NIH should fund root-cause research rather than just treatment-focused or DEI-description studies. The FDA should be a referee that enables innovation, not a gatekeeper that delays access when the evidence is strong and the unmet need is high.

Data Points: FDA reforms announced: 42 - Makary said the agency had announced 42 major reforms in his first 10 months. FDA staff before restructuring: 20,000 - He referenced total FDA staffing before cuts/consolidation. HR staff at FDA: 2,000 - He said there were 2,000 HR people just before he arrived. IT staff at FDA: 1,500 - He said there were 1,500 IT people before restructuring. Turnover rate: 5% to 7% - He said FDA turnover remains at the baseline rate of the last 10 years. New scientists being hired: 1,050 - He said the FDA is hiring 1,050 new scientists. User fee target dates hit: 100% - He said FDA met all user fee target dates in 2025. Drugs approved in one month: 9 - He said the Center for Biologics, Cell and Gene Therapies approved nine drugs last month. China licensing deal share: 5% in 2022 to 42% in 2025 - He cited licensing deal growth to illustrate China’s rise in biotech. U.S. race window: 3 years - He cited a commission warning the U.S. has a three-year window to act. IRB delay example: 1.5 years - A Johns Hopkins nutrition survey reportedly took a year and a half and still was not approved. FDA application completeness decision time: 60 days to 1 day target - He said the FDA used to take 60 days and wants to reduce this to one day using AI. Pivotal trials default: 2 to 1 - He announced a shift from requiring two pivotal trials to one in some cases. Cost savings per drug: $100M to $300M - He said moving from two to one pivotal trial can save companies this amount. Monoclonal antibody chimpanzee studies: 144 chimpanzees - He said old requirements used 144 chimpanzees for some monoclonal antibody testing. Animal testing predictiveness: 90% - He said 90% of drugs that pass animal studies do not pass safety/efficacy in humans. Continuous trial pilot timing: 55 days - He said the first medication under the pilot was announced after 55 days. Pilot vouchers issued: 18 - He said 18 products have vouchers for the new fast-track pilot. Core vaccine doses: 38 doses - He said the revised core essential vaccine list covers about 38 doses from age 0 to 18. Old U.S. vaccine schedule: 72 doses - He said the prior U.S. schedule had 72 recommended doses from ages 0 to 18. Childhood chronic disease: 40% - He said 40% of American kids have a chronic disease. Prediabetes/diabetes in kids: 38% - He said 38% of kids have pre-diabetes or diabetes. Refined carbohydrates in child calories: 60% to 70% - He said this share of calories comes from refined carbs. NIH budget: about $47 billion - He distinguished total NIH budget from grant dollars. NIH grants: about $40 billion per year - He referenced the approximate annual grants volume. DEI research share at NIH: 14% - He said 14% of NIH grants went to DEI research. GLP-1 price example: $1,300 in the U.S. vs $88 in London - He used this to argue for most-favored-nation pricing. GLP-1 first-three-month price target: $149 - He said the price would come down to $149 for the first three months. Biosimilar approval timeline: 5 to 8 years to about 2.5 years - He said FDA changes will shorten biosimilar approval time. Biosimilar development cost reduction: $100M+ - He said lower regulatory burden will reduce R&D costs by more than $100 million. FDA enforcement letters: 1,500 - He said he sent 1,500 enforcement letters, including cease-and-desist letters for misleading ads. Prior year enforcement letters: 0 - He said the Biden-era FDA sent zero enforcement letters in the prior year. Antibiotics unnecessary: 60% - He said 60% of antibiotics prescribed in the U.S. are unnecessary. Veteran suicides: 7,000+ per year - He cited this as motivation for PTSD treatment development. Pediatric antibiotic exposure: 2.5 courses by age 2 - He said the average two-year-old has already received over 2.5 courses of antibiotics.

Pivotal Quotes: "My number one priority is not to censor Americans, it's to deliver more cures and meaningful treatments faster to the American public and healthier food for children." — Marty Makary: He contrasted his FDA leadership philosophy with prior emphasis on misinformation control. "We are actually hiring 1,050 new scientists because we have very ambitious goals on our new pathways, accelerated-type pathways." — Marty Makary: He responded to criticism that the FDA is in turmoil or losing talent. "What are we doing? We have got to move at the speed that my patients demanded, not at government speed." — Marty Makary: He summarized his case for faster regulatory action and approval timelines.

Implications: If implemented, these changes could lower drug prices, speed access to treatments, and reshape FDA norms around evidence, safety, and oversight. The broader challenge is whether faster regulation can maintain trust while industry, states, and federal agencies adjust to a more aggressive model.